Lineage Cell Therapeutics
LCTX
123 hedge funds and large institutions have $170M invested in Lineage Cell Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 29 increasing their positions, 28 reducing their positions, and 12 closing their positions.
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
57% more call options, than puts
Call options by funds: $180K | Put options by funds: $115K
14% more capital invested
Capital invested by funds: $149M → $170M (+$21.2M)
10% more funds holding
Funds holding: 112 → 123 (+11)
5.63% more ownership
Funds ownership: 38.5% → 44.14% (+5.6%)
4% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$11.8M |
| 2 |
BlackRock
New York
|
+$2.78M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.36M |
| 4 |
Goldman Sachs
New York
|
+$2.24M |
| 5 |
Morgan Stanley
New York
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$2.73M |
| 2 |
Millennium Management
New York
|
-$986K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$588K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$530K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$257K |
LCTX Hedge Fund Activity: Q4 2025 in Review
123 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2025, worth a combined $170M — up 14% from $149M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LCTX positions and 12 closed out — a net gain of 13 holders — while 29 added to existing stakes and 28 trimmed.
The largest buyer was Defender Capital, opening a new position worth an estimated $11.8M. The largest seller was Dauntless Investment Group, exiting entirely with an estimated $2.73M sold.
- 123 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2025, up from 112 in Q3 2025.
- Funds reported $170M of Lineage Cell Therapeutics stock for Q4 2025, up 14% quarter-over-quarter.
- 25 funds opened new Lineage Cell Therapeutics positions in Q4 2025 and 12 closed out, a net change of +13 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2025 was Defender Capital, an estimated $11.8M added.
- The largest Lineage Cell Therapeutics seller in Q4 2025 was Dauntless Investment Group, an estimated $2.73M sold.
Based on aggregated 13F filings for Q4 2025.